Diatherix Laboratories Acquires Diagnostic Testing Patent, Prepares for Business Expansion

Huntsville, Ala., Aug. 7, 2013 /PRNewswire/ -- DIATHERIX Laboratories, Inc., today announced that it has acquired the patent to Tem-PCR, a diagnostic testing technology that allows for rapid identification of multiple infectious disease organisms. The acquisition from QIAGEN, a leading global provider of molecular sample and assay technologies, follows a multi-year agreement through which DIATHERIX licensed Tem-PCR from QIAGEN. Terms of the deal were not disclosed.

DIATHERIX operates as an independent CLIA-certified clinical laboratory providing advanced multiplex molecular diagnostic services to assist healthcare providers in the detection of infectious disease. With the patent acquisition, DIATHERIX plans to expand its business model to begin manufacturing and distributing diagnostic testing products to healthcare providers for on-site use. The goal is to speed the process of diagnosing and treating infectious diseases, thereby improving outcomes and lowering costs.

“We’re extremely pleased to acquire the patent to Tem-PCR,” said Dennis Grimaud, CEO of DIATHERIX Laboratories, Inc. “Putting this diagnostic technology in the hands of providers could reduce the time to diagnosis from 24 hours to as few as six to eight hours, speeding the treatment and healing process for patients and generating savings for providers by reducing patient infection rates, decreasing the amount of time patients need to be kept in isolation, and lowering prescription drug costs.”

DIATHERIX has begun expanding its space at the Hudson Alpha Institute for Biotechnology in Huntsville, Ala, to accommodate future manufacturing and distribution. It is also working with QIAGEN to reach a distribution and supply agreements to continue the companies’ long-time partnership.

“DIATHERIX has been an excellent partner for QIAGEN, and we look forward to continuing our relationship into the future,” said Dr. Ulrich Schriek, Senior Vice President Corporate Business Development of QIAGEN.

About DIATHERIX Laboratories, Inc.
DIATHERIX Laboratories, Inc. is located in the HudsonAlpha Institute for Biotechnology in Huntsville, Ala. DIATHERIX operates as an independent high complexity CLIA-certified clinical laboratory providing advanced multiplex molecular diagnostic services to assist healthcare providers in the detection of infectious disease. For more information, please visit the company’s website at www.DIATHERIX.com.

SOURCE DIATHERIX Laboratories, Inc.